DrugPatentWatch Database Preview
Sparc Company Profile
What is the competitive landscape for SPARC, and what generic alternatives to SPARC drugs are available?
SPARC has one approved drug.
There are five US patents protecting SPARC drugs.
There are twenty-three patent family members on SPARC drugs in eighteen countries and two supplementary protection certificates in two countries.
Summary for Sparc
| International Patents: | 23 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Sparc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sparc | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-002 | Dec 20, 2018 | RX | Yes | Yes | 8,425,938 | Start Trial | Y | Start Trial | |||
| Sparc | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-002 | Dec 20, 2018 | RX | Yes | Yes | 8,470,367 | Start Trial | Y | Start Trial | |||
| Sparc | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | RX | Yes | No | 8,431,156 | Start Trial | Y | Start Trial | |||
| Sparc | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | RX | Yes | No | 8,470,367 | Start Trial | Y | Start Trial | |||
| Sparc | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-002 | Dec 20, 2018 | RX | Yes | Yes | 8,535,717 | Start Trial | Y | Start Trial | |||
| Sparc | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | RX | Yes | No | 8,163,306 | Start Trial | Y | Start Trial | |||
| Sparc | ELEPSIA XR | levetiracetam | TABLET, EXTENDED RELEASE;ORAL | 204417-001 | Dec 20, 2018 | RX | Yes | No | 8,425,938 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Sparc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 1663175 | Start Trial |
| Brazil | PI0414305 | Start Trial |
| China | 1856299 | Start Trial |
| African Regional IP Organization (ARIPO) | 200603602 | Start Trial |
| South Africa | 200602276 | Start Trial |
| South Korea | 20060076307 | Start Trial |
| South Korea | 101164881 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sparc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0162036 | 2000C/032 | Belgium | Start Trial | PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329 |
| 0162036 | C300028 | Netherlands | Start Trial | PRODUCT NAME: LEVETIRACETAM; REGISTRATION NO/DATE: EU/1/00/146/001 - EU/1/00/146/026 20000929 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
